The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2018
Filed:
Dec. 21, 2016
Applicant:
Pharmacyclics Llc, Sunnyvale, CA (US);
Inventors:
David J. Loury, Incline Village, NV (US);
Joseph J. Buggy, Mountain View, CA (US);
Tarak D. Mody, Sunnyvale, CA (US);
Erik J. Verner, San Mateo, CA (US);
Norbert Purro, Los Gatos, CA (US);
Sriram Balasubramanian, North Wales, PA (US);
Assignee:
Pharmacyclics LLC, Sunnyvale, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/66 (2006.01); A61N 5/10 (2006.01); A61K 45/00 (2006.01); A61K 9/20 (2006.01); A61K 38/05 (2006.01); C07D 307/85 (2006.01); A61K 45/06 (2006.01); A61K 31/704 (2006.01); A61K 31/573 (2006.01); A61K 31/4184 (2006.01); A61K 47/12 (2006.01); A61K 47/02 (2006.01); A61K 31/69 (2006.01); A61K 31/497 (2006.01); A61K 31/47 (2006.01); A61K 31/40 (2006.01); A61K 31/381 (2006.01); A61K 31/35 (2006.01); A61K 31/343 (2006.01); A61K 31/166 (2006.01); A61K 9/50 (2006.01); A61K 9/48 (2006.01); A61K 9/28 (2006.01);
U.S. Cl.
CPC ...
A61N 5/10 (2013.01); A61K 9/205 (2013.01); A61K 9/2054 (2013.01); A61K 9/2826 (2013.01); A61K 9/2846 (2013.01); A61K 9/2866 (2013.01); A61K 9/4808 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/501 (2013.01); A61K 9/5026 (2013.01); A61K 31/166 (2013.01); A61K 31/343 (2013.01); A61K 31/35 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/4184 (2013.01); A61K 31/47 (2013.01); A61K 31/497 (2013.01); A61K 31/573 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 38/05 (2013.01); A61K 45/05 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); C07D 307/85 (2013.01);
Abstract
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.